A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - comment

Br J Dermatol. 2017 Oct;177(4):1004-1005. doi: 10.1111/bjd.15848. Epub 2017 Aug 31.
No abstract available

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Calcineurin Inhibitors / administration & dosage*
  • Calcineurin Inhibitors / adverse effects
  • Dermatitis, Atopic / drug therapy*
  • Dermatologic Agents / administration & dosage*
  • Dermatologic Agents / adverse effects
  • Humans
  • Tacrolimus / administration & dosage
  • Tacrolimus / adverse effects
  • Tacrolimus / analogs & derivatives*
  • Treatment Outcome

Substances

  • Calcineurin Inhibitors
  • Dermatologic Agents
  • pimecrolimus
  • Tacrolimus